Human technology after cardiac epigenesis. Artificial heart versus cardiac transplantation.
Cardiovascular disease is the chief cause of death in technologically advanced countries and accounts for more than 50% of all deaths in the USA. For a patient with end-stage cardiac failure the only treatment presently available is organ replacement, either by transplantation or by the use of a mechanical heart. Transplantation has demonstrated its value: survival of more than 8 years and restoration of a normal quality of life to patients who were in end-stage cardiac decompensation. However, the prospect of routine clinical application of an artificial heart remains distant. The development of a totally implantable artificial heart still presents a series of challenging engineering problems with regard to strict constraints of size, weight, blood-material compatibility, adaptability of output to demand, efficiency and reliability of the power supply, and safety if nuclear fuel is used. The totally artificial heart is presently not an alternative to the cardiac allograft, but could provide short-term support for patients awaiting cardiac transplantation.
D000743:Anemia, Hemolytic / Q000209:etiology; D000818:Animals; D011211:Electric Power Supplies; D016027:Heart Transplantation; D006354:Heart, Artificial / Q000009:adverse effects; D006439:Hemodynamics; D006801:Humans; D013923:Thromboembolism / Q000209:etiology; D014184:Transplantation, Homologous